EGFR and cervical carcinoma: MUC1 increased expression after paclitaxel treatment supports acquired chemoresistance via MUC1-C/EGFR complex nuclear activity, thereby EGFR inhibition by Erlonitib sensitized cells to paclitaxel, abrogated CD133 + cells enrichment and prevented disease relapse of cervical cancer [219].